I want to
slow my
FA
progression,
that’s why I'm
making moves
to
choose Skyclarys*

*In a 48-week clinical trial, treatment with SKYCLARYS resulted in less physical impairment over time versus placebo, as measured by the modified Friedreich Ataxia Rating Scale.

Patients featured are paid spokespersons for Biogen.

SKYCLARYS is the first and only FDA-approved prescription medicine to treat Friedreich ataxia (FA) in patients aged 16 years and older

People taking SKYCLARYS experienced less physical impairment over 48 weeks compared with people from the untreated group in the MOXIe clinical trial.

For a chance to slow FA progression, take SKYCLARYS as your doctor prescribes

Based on commercial patients, early access patients, and clinical trial participants through July 2024.

As of July 2024.

§As of November 2024.

In a 48-week clinical trial, treatment with SKYCLARYS resulted in less physical impairment over time versus placebo, as measured by the modified Friedreich Ataxia Rating Scale.

Stay Connected

I authorize Biogen, and companies working with Biogen, to contact me by mobile or online digital media, mail, email, fax, telephone call, and text message (including autodialed and prerecorded calls and messages) for marketing purposes or otherwise provide me with information about Biogen’s products, services, and programs or other topics of interest, conduct market research or otherwise ask me about my experience with or thoughts about such topics. I understand and agree that any information that I provide may be used by Biogen for marketing, including targeted online marketing, as well as to help develop new products, services, and programs. I understand that Biogen will not sell or transfer my personal data to any unrelated third party for marketing purposes without my express permission. I understand that my consent is not required as a condition of purchasing or receiving any goods or services from Biogen. I understand that I may revoke this authorization and choose not to receive information from Biogen by using the link provided in emails I receive from Biogen, clicking the “Unsubscribe” link at the bottom of this page, sending an email with the subject “Unsubscribe” to privacy@biogen.com, or mailing a letter to Biogen, 5000 Davis Drive, PO Box 13919, Research Triangle Park, NC, 27709. For more information visit biogen.com/privacy.

Residents of certain US States (including but not limited to California) may have additional rights regarding the collection, use, maintenance, disclosure, and deletion of your personal information. To understand or exercise those rights California residents please visit https://www.biogen.com/privacy-center/california-policy.html. For more information, visit https://www.biogen.com/privacy-center.html.

Thank you for connecting! We'll be in touch.